ENPP2 and metabolic disease: In particular, LPA production and/or autotaxin are increased in obesity-associated metabolic diseases [52], induced hypercholesterolemia [53], congenital lipodystrophy [54], as well as in ethanol-fed mice [55] and in patients with Alzheimer disease [56] or multiple sclerosis [57].